Compare Exelon Corporation Common Stock (EXC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelon Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? Exelon Corporation Common Stock trades at $43 (market cap $43.61B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Exelon Corporation Common Stock is far larger — about 3.9× Repligen Corporation Common Stock's market cap, and Exelon Corporation Common Stock pays a 3.97% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EXC | RGEN | |
|---|---|---|
Market Cap | $43.61B | $11.14B |
Volume | 5,642,975 | 1,259,263 |
Sector | Utilities | Health |
52-Week High | $50.29 | $194.57 |
52-Week Low | $40.20 | $102.87 |
Enterprise Value | $94.47B | $11.02B |
Dividend Yield | 3.97% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Exelon (EXC) trades at $42.34, up 0.52% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong earnings beats in recent quarters except for a Q2 2026 miss, with Q3 2026 results expected on October 30, 2026. Financials show solid profitability with a 10.99% net income margin and a P/E of 15.56, while cash flow trends indicate improving operational performance.
The outlook is cautiously optimistic, supported by a $48.11 analyst consensus price target and institutional accumulation, but risks include regulatory approvals for dividends and high RSI levels suggesting overbought conditions. Earnings growth and grid investment plans are key catalysts, though investor sentiment remains divided amid rate environment uncertainties.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelon Corporation Common Stock
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
